On June 18, 2025, Investing.com published two separate articles claiming Aurora Cannabis had entered into corporate agreements. The first stated Aurora agreed to acquire MedLeaf Therapeutics, a company based in New Zealand. The second claimed the company had partnered with MediPharm GmbH for cannabis distribution in European countries.
Aurora has now publicly confirmed that both reports are inaccurate.
Aurora’s Official Response
Aurora stated that it:
- Has not agreed to acquire MedLeaf Therapeutics
- Has no partnership or agreement with MediPharm GmbH
- Has had no discussions with either company about a business transaction
- Has not issued any information related to such deals
Both articles were labeled by Investing.com as having been created “with the support of AI” and underwent editorial review. Aurora has launched an internal investigation to discover the origin of these publications.
Caution to Investors
Aurora emphasized that it does not have any non-public information and warned investors not to rely on Investing.com for accurate updates about the company.
The company stated that any material corporate announcements will be released through official channels as required.
Aurora Cannabis
Aurora Cannabis Inc. is a global medical cannabis company operating in Canada, Europe, Australia, and New Zealand. Its brands serve both the medical and recreational markets. Aurora shares are publicly traded on the NASDAQ and TSX under the symbol ACB.
Rita Ferreira
Rita is a seasoned writer with over five years of experience, having worked with globally renowned platforms, including Forbes and Miister CBD. Her deep knowledge of hemp-related businesses and passion for delivering accurate and concise information distinguish her in the industry. Rita's contributions empower individuals and companies to navigate the complexities of the cannabis world, and her work remains a valuable resource for those seeking a deeper understanding of its potential.
